


**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name :** MR. SINGARAVELAN G

**Age / Gender :** 51 years / Male

**Patient ID :** 148125

**Referral :** MediWheel

Scan to Validate


**Billing Time :** Nov 25, 2023, 09:52 a.m.

**Collection Time :** Nov 25, 2023, 09:59 a.m.

**Reporting Time :** Nov 25, 2023, 05:35 p.m.

**Sample ID :**


000932923P

Test Description	Value(s)	Unit(s)	Reference Range
<b>COMPLETE BLOOD COUNT ( CBC )</b>			
Hemoglobin (Hb)	12.7	gm/dL	13.5 - 18.0
Erythrocyte (RBC) Count	4.68	mil/cu.mm	4.7 - 6.0
Packed Cell Volume (PCV)	39.3	%	42 - 52
Mean Cell Volume (MCV)	83.97	fL	78 - 100
Mean Cell Haemoglobin (MCH)	27.14	pg	27 - 31
Mean Corpuscular Hb Concn. (MCHC)	32.32	g/dL	32 - 36
Red Cell Distribution Width (RDW)	13.4	%	11.5 - 14.0
Total Leucocytes (WBC) Count	8200	cell/cu.mm	4000-10000
Neutrophils	64	%	40 - 80
Lymphocytes	28	%	20 - 40
Monocytes	7	%	2 - 10
Eosinophils	1	%	1 - 6
Basophils	0	%	1-2
Absolute Neutrophil Count	5248	/c.mm	2000 - 7000
Absolute Lymphocyte Count	2296	/c.mm	1000 - 3000
Absolute Monocyte Count	574	/c.mm	200 - 1000
Absolute Eosinophil Count	82	/c.mm	20 - 500
Absolute Basophils Count	0	/c.mm	20 - 100
Platelet Count	348	10 <sup>3</sup> /ul	150 - 450
Mean Platelet Volume (MPV)	9.6	fL	7.2 - 11.7
PCT	0.33	%	0.2 - 0.5
PDW	9.9	%	9.0 - 17.0
ESR	15.0	mm/hr	13.5 - 18.0

 DR.K.MURALEKAARTHIC  
 MD(Patho)


**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

Patient Name : MR. SINGARAVELAN G

Age / Gender : 51 years / Male

Patient ID : 148125

Referral : MediWheel

Scan to Validate



Billing Time : Nov 25, 2023, 09:52 a.m.

Collection Time : Nov 25, 2023, 09:59 a.m.

Reporting Time : Nov 25, 2023, 05:35 p.m.

Sample ID :



000932923P

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

**URINE COMPLETE ANALYSIS,**
**Physical Examination**

Quantity	25	ml	-
Colour	Pale Yellow		Pale yellow/Yellow
Appearance	Cloudy		Clear
Specific Gravity	1.025		1.005-1.025
pH	6.5		5.0 - 8.0
Deposit	<b>Present</b>		Absent

**Chemical Examination**

Protein	Absent		Absent
Sugar	Absent		Absent
Ketones	Absent		Absent
Bile Salt	Absent		Absent
Bile Pigment	Absent		Absent
Urobilinogen	Normal		Normal

**Microscopic Examination (/hpf)**

Pus Cell	4-5		Upto 5
Epithelial Cells	2-4		Upto 5
Red Blood Cells	Absent		Absent
Casts	Absent		Absent
Crystals	Absent		Absent
Amorphous Deposit	Absent		Absent
Yeast Cells	Absent		Absent
Bacteria	<b>Present</b>		Absent
Other findings	Not seen		Not seen

 DR.K.MURALEKAARTHIC  
 MD(Patho)



**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name** : MR. SINGARAVELAN G

**Age / Gender** : 51 years / Male

**Patient ID** : 148125

**Referral** : MediWheel

Scan to Validate



**Billing Time** : Nov 25, 2023, 09:52 a.m.

**Collection Time** : Nov 25, 2023, 09:59 a.m.

**Reporting Time** : Nov 25, 2023, 05:35 p.m.

**Sample ID** :



000932923P

Test Description	Value(s)	Unit(s)	Reference Range

DR.K.MURALEKARTHIC  
MD(Patho)



**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name** : MR. SINGARAVELAN G

**Age / Gender** : 51 years / Male

**Patient ID** : 148125

**Referral** : MediWheel

Scan to Validate



**Billing Time** : Nov 25, 2023, 09:52 a.m.

**Collection Time** : Nov 25, 2023, 09:59 a.m.

**Reporting Time** : Nov 25, 2023, 05:35 p.m.

**Sample ID** :



000932923P

Test Description	Value(s)	Unit(s)	Reference Range
<b><u>BLOOD GROUP &amp; RH TYPING</u></b>			
Blood Group (ABO typing) Method : Manual-Hemagglutination	"O"		
RhD Factor (Rh Typing) Method : Manual hemagglutination	Positive		

DR.K.MURALEKARTHIC  
MD(Patho)


**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name :** MR. SINGARAVELAN G

**Age / Gender :** 51 years / Male

**Patient ID :** 148125

**Referral :** MediWheel

Scan to Validate


**Billing Time :** Nov 25, 2023, 09:52 a.m.

**Collection Time :** Nov 25, 2023, 09:59 a.m.

**Reporting Time :** Nov 25, 2023, 05:35 p.m.

**Sample ID :**


000932923P

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

**Glycosylated HbA1c**
**HbA1c (GLYCOSYLATED HEMOGLOBIN)**

5.5

%

Method : (HPLC, NGSP certified)

Estimated Average Glucose :

111.15

mg/dL

-

**Interpretation**

As per American Diabetes Association (ADA)	
Reference Group	HbA1c in %
Non diabetic adults >=18 years	<5.7
At risk (Prediabetes)	5.7 - 6.4
Diagnosing Diabetes	>= 6.5
Therapeutic goals for glycemic control	Age > 19 years Goal of therapy: < 7.0 Action suggested: > 8.0 Age < 19 years Goal of therapy: <7.5

 DR.K.MURALEKARTHIC  
 MD(Patho)



**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name** : MR. SINGARAVELAN G

**Age / Gender** : 51 years / Male

**Patient ID** : 148125

**Referral** : MediWheel

Scan to Validate



**Billing Time** : Nov 25, 2023, 09:52 a.m.

**Collection Time** : Nov 25, 2023, 09:59 a.m.

**Reporting Time** : Nov 25, 2023, 05:35 p.m.

**Sample ID** :



000932923P

Test Description	Value(s)	Unit(s)	Reference Range
<b><u>THYROID PROFILE TEST - TOTAL</u></b>			
T3-Total	112.0	ng/dL	60 - 200
T4-Total	10.5	ug/dL	4.52 - 12.8
TSH-Ultrasensitive	3.42	uIU/mL	0.32 - 5.5
Method : CLIA			

DR.K.MURALEKARTHIC  
MD(Patho)


**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name :** MR. SINGARAVELAN G

**Age / Gender :** 51 years / Male

**Patient ID :** 148125

**Referral :** MediWheel

Scan to Validate


**Billing Time :** Nov 25, 2023, 09:52 a.m.

**Collection Time :** Nov 25, 2023, 09:59 a.m.

**Reporting Time :** Nov 25, 2023, 05:35 p.m.


**Sample ID :**


000932923P

Test Description	Value(s)	Unit(s)	Reference Range
<b><u>LIPID PROFILE</u></b>			
Cholesterol-Total Method : Spectrophotometry	198.0	mg/dL	Desirable level   < 200 Borderline High   200-239 High   >or = 240
Triglycerides Method : Serum, Enzymatic, endpoint	<b>185.0</b>	mg/dL	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500
HDL Cholesterol Method : Serum, Direct measure-PEG	48.0	mg/dL	Normal: > 40 Major Risk for Heart: < 40
LDL Cholesterol Method : Enzymatic selective protection	113	mg/dL	Optimal < 100 Near / Above Optimal 100-129 Borderline High 130-159 High 160-189 Very High >or = 190
VLDL Cholesterol Method : Serum, Enzymatic	37	mg/dL	6 - 38
CHOL/HDL Ratio Method : Serum, Enzymatic	4.13		3.5 - 5.0
LDL/HDL Ratio Method : Serum, Enzymatic	<b>2.35</b>		2.5 - 3.5

**Note:**

8-10 hours fasting sample is required.

  
 DR.K.MURALEKAARTHIC  
 MD(Patho)


**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name :** MR. SINGARAVELAN G

**Age / Gender :** 51 years / Male

**Patient ID :** 148125

**Referral :** MediWheel

Scan to Validate


**Billing Time :** Nov 25, 2023, 09:52 a.m.

**Collection Time :** Nov 25, 2023, 09:59 a.m.

**Reporting Time :** Nov 25, 2023, 05:35 p.m.

**Sample ID :**


000932923P

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

**RENAL PROFILE**

Urea Method : Uricase	22.0	mg/dL	19-42
Blood Urea Nitrogen-BUN Method : Serum, Urease	10.27	mg/dL	9-20
Creatinine Method : Serum, Jaffe	1.04	mg/dL	0.66-1.25
Uric Acid Method : Serum, Uricase	<b>1.4</b>	mg/dL	3.5-8.5

**Remark:**

In blood, Urea is usually reported as BUN and expressed in mg/dl. BUN mass units can be converted to urea mass units by multiplying by 2.14.

 DR.K.MURALEKAARTHIC  
MD(Patho)





**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name** : MR. SINGARAVELAN G

**Age / Gender** : 51 years / Male

**Patient ID** : 148125

**Referral** : MediWheel

Scan to Validate



**Billing Time** : Nov 25, 2023, 09:52 a.m.

**Collection Time** : Nov 25, 2023, 09:59 a.m.


**Reporting Time** : Nov 25, 2023, 05:35 p.m.

**Sample ID** :



000932923P

Test Description	Value(s)	Unit(s)	Reference Range
<b><u>LIVER FUNCTION TEST</u></b>			
Total Protein Method : Serum, Biuret, reagent blank end point	7.3	g/dL	6.3-8.2
Albumin Method : Serum, Bromocresol green	4.1	g/dL	3.5-5.0
Globulin Method : Serum, EIA	3.20	g/dL	1.8 - 3.6
A/G Ratio Method : Serum, EIA	1.28		1.2 - 2.2
Bilirubin - Total Method : Serum, Jendrassik Grof	0.6	mg/dL	0.3-1.2
Bilirubin - Direct Method : Serum, Diazotization	0.1	mg/dL	< 0.2
Bilirubin - Indirect Method : Serum, Calculated	0.50	mg/dL	0.1 - 1.0
SGOT Method : Serum, UV with P5P, IFCC 37 degree	21.0	U/L	17-59
SGPT Method : Serum, UV with P5P, IFCC 37 degree	26.0	U/L	21-72
Alkaline Phosphatase Method : PNPP-AMP Buffer/Kinetic	100.0	U/L	30 - 120
GGT-Gamma Glutamyl Transpeptidase Method : Serum, G-glutamyl-carboxy-nitroanilide	35.0	U/L	< 55

  
DR.K.MURALEKAARTHIC  
MD(Patho)


**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name** : MR. SINGARAVELAN G

**Age / Gender** : 51 years / Male

**Patient ID** : 148125

**Referral** : MediWheel

Scan to Validate


**Billing Time** : Nov 25, 2023, 09:52 a.m.

**Collection Time** : Nov 25, 2023, 09:59 a.m.

**Reporting Time** : Nov 25, 2023, 05:35 p.m.

**Sample ID** :


000932923P

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

**PSA-Total (Prostate-specific antigen-Total)**
**PSA Profile \***

PSA (Prostate Specific Antigen)-Total	0.47	ng/mL	0 - 4.0
---------------------------------------	------	-------	---------

Method : Serum, CLIA

**Interpretation:**

1. Increased levels are noted in Prostate cancer, Benign prostatic hypertrophy, Prostatitis

PSA (Prostate-Specific antigen)-Free *	-	ng/mL	0.0 - 0.5
--	---	-------	-----------

Method : Serum, CLIA

**Interpretation & Remarks:**

- Normal results do not eliminate the possibility of prostate cancer.
- Values obtained with different assay methods or kits may be different and cannot be used interchangeably.
- Tumor markers are not specific for malignancy. Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease
- Specimens drawn from patients undergoing prostate manipulation, especially needle biopsy and transurethral resection, may show erroneously high prostatic-specific antigen (PSA) results. Care should be taken that specimens are drawn before these procedures are performed.
- The percentage of free PSA can be used to estimate how likely it is that a biopsy will show cancer.
- If the percentage of free PSA is higher than 25%, the likelihood of prostate cancer is about 8%.
- If the percentage of free PSA is less than 10%, then the likelihood of prostate cancer rises to 56%.

Free PSA / Total PSA %	-	-
------------------------	---	---

Method : Serum

**Interpretation**

- When total prostate-specific antigen (PSA) concentration is <2.0 ng/mL, the probability of prostate cancer in asymptomatic men is low, further testing and free PSA may provide little additional information. When total PSA concentration is >10.0 ng/mL, the probability of cancer is high and prostate biopsy is generally recommended.
- The total PSA range of 4.0 to 10.0 ng/mL has been described as a diagnostic "gray zone," in which the free:total PSA ratio helps to determine the relative risk of prostate cancer (see table below). Therefore, some urologists recommend using the free:total ratio

 DR.K.MURALEKARTHIC  
MD(Patho)


**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name :** MR. SINGARAVELAN G

**Age / Gender :** 51 years / Male

**Patient ID :** 148125

**Referral :** MediWheel

Scan to Validate


**Billing Time :** Nov 25, 2023, 09:52 a.m.

**Collection Time :** Nov 25, 2023, 09:59 a.m.

**Reporting Time :** Nov 25, 2023, 05:35 p.m.

**Sample ID :**


000932923P

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

to help select which men should undergo biopsy. However even a negative result of prostate biopsy does not rule-out prostate cancer. Up to 20% of men with negative biopsy results have subsequently been found to have cancer.

Based on free:total PSA ratio: the percent probability of finding prostate cancer on a needle biopsy by age in years:

Free:total PSA ratio	50-59 years	60-69 years	> or =70 years
< or =0.10	49.2%	57.5%	64.5%
0.11-0.18	26.9%	33.9%	40.8%
0.19-0.25	18.3%	23.9%	29.7%
>0.25	9.1%	12.2%	15.8%

**Cautions**

- Normal results do not eliminate the possibility of prostate cancer.
- Values obtained with different assay methods or kits may be different and cannot be used interchangeably
- Tumor markers are not specific for malignancy. Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease.

**Interfering factors :**

- Prostatic massage
- Proctoscopy
- Prostatic biopsy
- Prostate cancer patients receiving treatment with antiandrogens and luteinizing hormone-releasing factor agonists may exhibit markedly decreased levels of PSA. Also, men treated for benign prostatic hyperplasia with inhibitors of 5-alpha-reductase (finasteride) may demonstrate a significant reduction in PSA levels compared to values before treatment. Care should be taken in interpreting values for these individuals.
- In patients receiving therapy with high biotin doses (ie, >5 mg/day), no sample should be taken until at least 8 hours after the last biotin administration.

 DR.K.MURALEKAARTHIC  
MD(Patho)



**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name :** MR. SINGARAVELAN G

**Age / Gender :** 51 years / Male

**Patient ID :** 148125

**Referral :** MediWheel

Scan to Validate



**Billing Time :** Nov 25, 2023, 09:52 a.m.

**Collection Time :** Nov 25, 2023, 09:59 a.m.

**Reporting Time :** Nov 25, 2023, 05:35 p.m.

**Sample ID :**



000932923P


Test Description	Value(s)	Unit(s)	Reference Range
<b><u>GLUCOSE (F)</u></b>			
Glucose fasting Method : GOD-POD	86.0	mg/dL	70 - 120

DR.K.MURALEKARTHIC  
MD(Patho)



# ABI SCANS & LABS<sup>TM</sup>

Accurate | Available | Affordable



**Patient Name :** MR. SINGARAVELAN G

**Age / Gender :** 51 years / Male

**Patient ID :** 148125

**Referral :** MediWheel

Scan to Validate



**Billing Time :** Nov 25, 2023, 09:52 a.m.

**Collection Time :** Nov 25, 2023, 09:59 a.m.

**Reporting Time :** Nov 25, 2023, 05:35 p.m.

**Sample ID :**



000932923P

Test Description	Value(s)	Unit(s)	Reference Range
<b><u>GLUCOSE (PP)</u></b>			
Blood Glucose-Post Prandial Method : GOD-POD	124.0	mg/dL	80 - 140

DR.K.MURALEKARTHIC  
MD(Patho)

594, Obli Towers,  
Db Road Cowley Brown  
Road Junction, Rs Puram,  
Coimbatore - 641 002.


A-17, Near  
Mahalingapuram  
Arch, Kamaraj Road,  
Pollachi - 642 002.

452/493, Miller Stop,  
PN Road,  
Tiruppur - 641 602.

+91 99430 99994

info@abiscans.com

www.abiscans.com



Patient Name	MR. SINGARAVELAN G	Age	51Yr
Patient ID	148125	Sex	Male
Referral Dr	MEDIWHEEL	Study Date	25 Nov 2023

### **USG REPORT - ABDOMEN AND PELVIS**

#### **LIVER:**

**Is increased in size ~ 16.5 cm and shows increased echo texture.**

No obvious focal lesion seen. No intra – Hepatic biliary radical dilatation seen.

#### **GALL BLADDER:**

Is adequately distended. No calculus or internal echoes are seen. Wall thickness is normal.

#### **PANCREAS:**

Appears normal in size and it shows uniform echo texture.

#### **SPLEEN:**

Is normal in size ~ 9.8 cm and shows uniform echogenicity.

#### **RIGHT KIDNEY:**

Right kidney measures ~ 10 x 3 cms.

The shape, size and contour of the right kidney appear normal.

Cortico medullary differentiation is within normal. No evidence of pelvicalyceal dilatation.

No calculi seen.

#### **LEFT KIDNEY:**

Left kidney measures ~ 9.7 x 4.4 cms.

The shape, size and contour of the left kidney appear normal.

Cortico medullary differentiation is within normal. No evidence of pelvicalyceal dilatation.


**Calculus of size measuring ~ 6 mm noted in lower pole of left kidney.**

#### **URINARY BLADDER:**

Is normal contour. No intra luminal echoes are seen.

#### **PROSTATE:**

Prostate appears normal, Measures ~ 2.4 x 3.5 x 2.1 cms (Vol – 9.6 cc).



Patient Name	MR. SINGARAVELAN G	Age	51Yr
Patient ID	148125	Sex	Male
Referral Dr	MEDIWHEEL	Study Date	25 Nov 2023

**RIGHT ILIAC FOSSA:**


No focal fluid collections seen.

No evidence of hernia seen in anterior abdominal wall.

**IMPRESSION:**

- Hepatomegaly with grade II fatty liver.
  - Non obstructive left intra renal calculus.
- Suggested clinical correlation.

Dr. Abinaya., MD., (RD)  
Consultant Radiologist



Patient Name	MR. SINGARAVELAN G	Age	51Yr
Patient ID	158052	Sex	Male
Referral Dr	MEDIWHEEL	Study Date	25 Nov 2023

**X-RAY - CHEST PA VIEW**

**OBSERVATION:**

The trachea is central.  
Unfolding of aorta seen- probably age related .  
The mediastinal and cardiac silhouette are normal.  
Cardiothoracic ratio is normal.  
Cardiophrenic and costophrenic angles are normal.  
Both hila are normal.  
Lung zones are clear.  
Bones of the thoracic cage are normal.  
Soft tissues of the chest wall are normal.

**IMPRESSION:**

**No significant abnormality seen.**

Dr. Lokesh Babu., MD., (RD)  
Consultant Radiologist